Supported by this rationale, we are conducting a Phase I clinical trial (NCT02414269) to evaluate the safety of regionally administered MSLN-targeted CAR T cells in patients with either primary pleural malignancies (MPM) or secondary pleural malignancies (lung and breast cancers) with MSLN expression. This evidence concerns the gene MSLN and breast cancer.